A non-inferiority trial comparing two recombinant vaccines (Hepa-B vs. Engerix-B) for hepatitis B among adults in Dhaka, Bangladesh
Vaccine. 2021 Sep 21:S0264-410X(21)01222-6. doi: 10.1016/j.vaccine.2021.09.031. Online ahead of print.ABSTRACTWorldwide Hepatitis B is known as one of the imperative causes of mortality and morbidity as well as occupational health hazard among health workers. Bangladesh is intermediate endemic country for Hepatitis B infection for which the government has introduced hepatitis B vaccination into the Expanded Programme on Immunization (EPI) nationwide since 2009 for new born children. However, the people who were born before 2009, was dependent on imported hepatitis B vaccine as there was no locally manufactured hepatitis B vaccine in Bangladesh. Hence, we conducted a randomized observer blinded non-inferiority clinical trial to assess the immunogenicity and safety of the locally manufactured Hepa-B vaccine in comparison with World Health Organization prequalified Engerix-B vaccine. Total 158 eligible adult participants were enrolled in this study with mean age of 30 and 29 years old in Hepa-B and Engerix-B groups, respectively. Both the vaccines were administered intramuscularly at 0, 1 and 6 months schedule. Baseline and post vaccination anti-HBs titers were measure at different time points. Seroconversion rate post three doses of Hepa-B vaccine was 98.67% similar to the comparator Engerix-B vaccine which was 100%. The geometric mean test ratios of both vaccines at all analysis time points were found > 0.5 predefined non-inferiority margin. Soreness at the injection site w...
Source: Vaccine - Category: Allergy & Immunology Authors: Fahima Chowdhury Afroza Akter Taufiqur Rahman Bhuiyan Imam Tauheed Tasnuva Ahmed Faisal Ahmmed Faez Ahmed Mahbubul Karim Mohammad Mainul Ahasan Masudur Rahman Mia Mir Mohammad Ibna Masud Abdul Wahab Khan Muhammad Masum Billah Zebun Nahar Imran Khan Md Rah Source Type: research
More News: Allergy & Immunology | Bangladesh Health | Children | Clinical Trials | Endemics | Government | Hepatitis | Hepatitis B | Hepatitis Vaccine | International Medicine & Public Health | Occupational Health | Study | Vaccines | WHO